Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD） - Trial NCT05795517
Access comprehensive clinical trial information for NCT05795517 through Pure Global AI's free database. This Phase 2 trial is sponsored by Haisco Pharmaceutical Group Co., Ltd. and is currently Recruiting. The study focuses on Hypercholesterolemia. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Haisco Pharmaceutical Group Co., Ltd.
Timeline & Enrollment
Phase 2
Apr 26, 2023
Feb 08, 2024
Primary Outcome
Percentage change in LDL-C from baseline at 12 week;,Percentage change in MRI-PDFF from baseline at 12 week；
Summary
The purpose of this study is to assess the efficacy and safety of HSK31679 tablets compared
 with placebo in reducing low-density lipoprotein cholesterol (LDL-C) and MRI-PDFF after 12
 weeks of treatment in patients with hypercholesterolemia and non-alcoholic fatty liver
 disease (NAFLD).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05795517
Non-Device Trial